Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRND | Q07001 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24535255 | 0.89 | — | — | |
| SCHEMBL370175 | 0.88 | MAOA (0.39) | KDM4ESLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL351208 | 0.86 | DHFR (0.32) | KDM4ESLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL10177371 | 0.82 | MEN1 (0.31) | HPGDSMN1; SMN2CYP1A2CYP2C19NPC1 | |
| SCHEMBL352055 | 0.81 | MAPT (0.46) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL10280919 | 0.80 | KDM4E (0.32) | KDM4ESLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL350079 | 0.78 | NSD2 (0.32) | ALDH1A1MAPT | |
| SCHEMBL352304 | 0.76 | HTR7 (0.36) | KDM4EALDH1A1SMN1; SMN2MAPTHTT | |
| SCHEMBL366604 | 0.76 | KDM4E (0.40) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL370091 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | claimed |
| US-9255074-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-02-09 | — | — | US | claimed |
| EP-2887941-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | AbbVie Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| US-8895737-B2 | Process for preparing antiviral compounds | ABBVIE INC. | 2014-11-25 | — | — | US | claimed |
| WO-2014031791-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | claimed |
| EP-2593439-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| WO-2012009699-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | claimed |
| EP-3461556-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | AbbVie Ireland Unlimited Company (IE) | 2019-04-03 | — | — | EP | disclosed |
| EP-3415504-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2018-12-19 | — | — | EP | disclosed |
| EP-3056486-B1 | PROCESS FOR PREPARING INTERMEDIATES FOR ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2887941-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | disclosed |
| US-9732045-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2593439-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009699-A2 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | KDM4E 3729/4885SLC6A3 1859/4885CHRNA1 4855/4885 |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | KDM4E 3762/4885SLC6A3 3906/4885CHRNA1 4403/4885 |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, MAVS, RNASE1 | KDM4E 3572/4885SLC6A3 1535/4885CHRNA1 4858/4885 |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | KDM4E 3814/4885SLC6A3 3119/4885CHRNA1 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.